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The contemporary management of splenic artery
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Vikram S. Kashyap MD,a Cleveland, Ohio
Objectives: The management of patients with splenic artery aneurysms (SAAs) is variable since the natural history of these
aneurysms is poorly delineated. The objective of this study was to review our experience with open repair, endovascular
therapy, and observation of SAAs over a 14-year interval.
Methods: Between January 1, 1996 and December 31, 2009, 128 patients with SAAs were evaluated. Sixty-two patients
underwent surgical repair (n  13) or endovascular coil/glue ablation (n  49), while 66 patients underwent serial
observation. The original medical records and computed tomography (CT) imaging were reviewed. Statistical analyses
were performed using 2 or Fisher’s exact test for categorical patient characteristics and t-test for continuous variables.
Kaplan-Meier estimates for survival were calculated. Mortality was verified via the Social Security Death Index.
Results: Patients (61  11 years, 69% female) were investigated for abdominal symptoms (49%) or had the incidental
finding of SAA (mean size, 2.4 1.4 cm). Seven patients (5.5%) presented with rupture and were treated emergently with
two perioperative mortalities (29%). Patients requiring surgical or endovascular treatment were more likely male (40% vs
21%, P  .031), younger (58 vs 64 years; P  .004), and current smokers (18% vs 5%; P  .035). Increased aneurysm
calcification was associated with decreased SAA size (P  .013). The mean aneurysm size at initial diagnosis was 1.67 cm
for patients undergoing observation and 3.13 cm for the treated group (P < .001). Endovascular repair was safe and
durable with a mean 1.5-mm regression in SAA size over 2 years. The mean rate of growth for observed SAA was 0.2
mm/y. Ten-year survival was 89.4% (95% confidence interval: 82.0, 97.4) for all patients (observed group, 94.9%; treated
group, 85.1%; P  .18). No late aneurysm-related mortality was identified.
Conclusions: Ruptured SAAs are lethal. Large SAAs can undergo endovascular ablation safely with durable SAA
regression. Smaller SAAs (<2 cm) grow slowly and carry a negligible rupture risk. ( J Vasc Surg 2011;53:958-65.)
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iSplenic artery aneurysms (SAAs) are the third most
common abdominal aneurysm preceded only by aortic and
iliac artery aneurysms, and comprise the majority of visceral
artery aneurysms.1 Despite this fact, SAAs are relatively rare
and remain an insidious entity. Incidental diagnosis is often
“presumptive” based on circular calcified shadows seen in
the left upper quadrant of an abdominal roentgenogram.2
Previous reports indicate a high rate of visceral aneurysm
rupture underscoring the serious nature of this disease
process.3
Retrospective reviews of nonselective angiograms have
provided the most reliable incidence estimate of approxi-
mately 0.8%.4 With the increasingly widespread use of axial
imaging techniques, the incidental detection of visceral
aneurysms is also increasing. However, the absence of a
well-defined natural history for SAAs has caused clinical
management to be based on historical guidelines. In addi-
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958ion, the advent of a minimally invasive endovascular treat-
ent for SAAs may possibly alter the risk-benefit analysis of
ntervention.
There has been a growing acceptance for treating vis-
eral artery aneurysms with endovascular modalities, but
vidence-based data and long-term follow-up have re-
ained elusive.5 The decision to observe or proceed with
urgical repair for SAAs has been hampered by the limited
atural history data. Recently, endovascular ablative ther-
py has emerged as a viable treatment option.5-7 The
urpose of this study was to describe our single-center
xperience with the management of SAAs.
ATIENTS AND METHODS
Between January 1, 1996 and December 31, 2009,
atients who presented to the Cleveland Clinic with a
iagnosis of an SAA were identified and reviewed. The
tudy was approved by the Cleveland Clinic Foundation
nstitutional Review Board. Patients (n  128) were iden-
ified during the study interval using ICD-9 codes 442.83
splenic artery aneurysm) and 442.84 (other visceral artery
neurysm). Sixty-two (48.4%) patients underwent surgical
epair (n  13; 10 open, 3 laparoscopic) or endovascular
oil/glue ablation (n  49), while 66 (51.6%) patients
nderwent serial observation. All demographic and clinical
ata were obtained through review of electronic medical
ecords. The indications for additional office visits or imag-
ng studies, for both treated and observed patients, were at
he discretion of the attending physician.
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Volume 53, Number 4 Lakin et al 959Preoperative demographic data and clinical variables
were collected. Pertinent risk factors assessed included
age, gender, hypertension, diabetes, hyperlipidemia,
coronary artery disease, and tobacco use. Only five
women in the cohort were of child-bearing age, and all
had negative pregnancy testing at time of presentation.
Patients were also assessed for whether their SAA was an
incidental finding, symptomatic, or ruptured at presen-
tation. Aneurysms were considered incidental findings if
the patient was receiving an imaging study for a separate
established diagnosis.
Pseudoaneurysms were distinguished from true aneu-
rysms by imaging criteria and both were included in the
analysis. There were a total of six (4.7%) pseudoaneurysms
in our series, with five occurring in the setting of acute or
chronic pancreatitis. The difference between pseudoaneu-
rysm and true aneurysm was based on radiographic findings
of focal arterial disruption and surrounding inflammation
in the setting of an irregular aneurysmal wall. All pseudoa-
neurysms in this series were treated by endovascular means.
The mean initial size of the pseudoaneurysms (n  6) was
34.8 mm compared with 30.9 mm for the true aneurysm-
treated group (P .29). There was one anomalous splenic
artery arising from the superior mesenteric artery; a known
anomaly occurring in approximately 1% of the population.8
Preoperative and postoperative imaging consisted of
duplex scanning, computed tomography (CT), magnetic
resonance imaging, angiography, or a combination of
these. Images were reviewed to confirm preoperative diag-
nosis and exact size. Calcification, thrombosis, size change,
and postoperative splenic infarction were assessed with the
assistance of three-dimensional (3-D) reconstruction of
Fig 1. A 54-year-old female underwent arterial-phase computed
tomography imaging during an evaluation for flank pain attributed
to kidney stones. This three-dimensional reconstruction image
illustrates the tortuosity of the splenic artery and the incidentally
discovered egg-shell appearance of a 2.7-cm midsplenic artery
aneurysm.axial imaging (TeraRecon Inc, version 3.7; San Mateo, talif) (Fig 1). Calcification was graded subjectively as (0)
or no calcification, (1) for 40% circumferential calcifica-
ion, or (2) for40% circumferential calcification based on
stablished scoring methods.9
The endovascular technique included occluding the
utflow tract, the aneurysm itself, and the inflow artery (Fig
) as described previously.7 All patients undergoing elective
epair received intraoperative heparinization to achieve an
ctivated clotting time of 250 seconds. Technical success
as defined as successful deployment of coils and/or glue
nto the intended artery segments, with angiographic doc-
mentation of aneurysmal occlusion or very sluggish flow
ith heparinization. A total of three patients in the endo-
ascular group had concomitant celiac artery aneurysms,
nd one of these patients had a stent graft placed into their
eliac axis during the same procedure.
Data analysis and statistical methods. Peripro-
edural data, associated morbidity, and 30-day mortality
ate were analyzed. For the endovascular group, postoper-
tive imaging was assessed for successful aneurysm ablation,
neurysm size change, and adequacy of end-organ perfu-
ion. Follow-up documentation of successful aneurysm
reatment included successful resolution of symptoms in
elected cases, and absence of flow on follow-up imaging.
ny mortalities in the cohort were verified through chart
eview and the Social Security Death Index. Mean
ollow-up for the cohort was 4.9  3 years (median 4.4,
uartiles 2.6, 6.7 years).
All statistical analyses were performed using R software
version 2.8; Vienna, Austria). Categorical factors were
ummarized using frequencies and percentages, while con-
inuous measure distributions were described using means,
tandard deviations, and quartiles of interest. Categorical
atient characteristics were compared between groups us-
ng Pearson 2 test or Fisher’s exact test when the expected
ell count was small. Continuous measures were compared
sing two-sample t-tests or Wilcoxon rank-sum tests as
ppropriate. Associations between calcification and initial
ize or change in size were performed using Spearman
orrelation, while the associations between preoperative
AA thrombus and initial size or change in size were
erformed using Wilcoxon rank-sum tests. Kaplan-Meier
stimates of survival were fit, and distributions were com-
ared using log-rank tests. A significance level of .05 was
ssumed for all tests.
ESULTS
SAA was diagnosed and clinically managed in 128
atients during this study interval. The mean age at diag-
osis was 61 years, and 69.5% of the cohort were female
Table I). The most common comorbidities were hyperten-
ion (52%) and hyperlipidemia (44%). A minority of pa-
ients (11%) were currently using tobacco. The mean size of
he SAA at diagnosis was 2.4  1.4 cm. Patients with
maller SAAs (n  66; mean size, 1.7  0.6 cm) were
erially observed by their primary physician or a vascular
urgeon (66%). Abdominal symptoms prompted evalua-
ion in nearly half the patients, but none of the abdominal
l
S
i
s
i
f
T
y
t
p
t
JOURNAL OF VASCULAR SURGERY
April 2011960 Lakin et alsymptoms were thought to be referable to the SAA in the
observed group.
Review of the preoperative imaging allowed accurate
size measurement, along with assessment of the degree of
SAA thrombosis and calcification (Fig 3). No relationship
was seen between the SAA initial size and the presence of
thrombus within the aneurysm (1.8 vs 2.25 cm; P  .6).
Calcification scoring was possible in 110 (86%) of the 128
cases. There was a significant negative relationship between
initial size and calcification level; as calcification level
increased, the initial size tended to decrease (Table II).
SAAs with the greatest calcification scores measured 1.75
cm, while SAAs without calcification measured 2.7 cm
Fig 2. Endovascular ablation of a splenic artery aneury
aortography showing the SAA on a delayed image. B, Se
outflow vessel, aneurysm sac, and inflow vessel. C, Comp
visible in the vessels and aneurysm sac.(P  .013). tSixty-two patients with SAAs underwent endovascu-
ar therapy (n 49) or open repair (n 13) for enlarged
AAs or rupture. There were four patients who were
nitially observed with serial imaging, but were then
cheduled for elective endovascular ablation based on
nterval growth.
Mean initial aneurysm size was 3.1  1.6 cm (2.9 cm
or the endovascular group and 4.4 cm for the open group).
reated patients were more likely to be male (P  .031),
ounger (P  .004), and be current smokers (P  .035)
han observed patients (Table I). Thirty-one (50%) of the
atients who were treated had abdominal symptoms at
he time of initial diagnosis. Hemodynamic instability in
AA). A, Transfemoral access with nonselective catheter
e splenic artery angiography. Coils are then placed into
aortography confirming occlusion of the SAA. Coils aresm (S
lectiv
letionhe setting of free rupture warranted emergent laparotomy
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Volume 53, Number 4 Lakin et al 961in six cases, with SAA resection and concomitant splenec-
tomy. An additional patient with a contained rupture un-
Fig 3. Evolution of a splenic artery aneurysm (SAA) A, An inci-
dentally noted 2.6-cm partially thrombosed SAA was noted on a
chest computed tomography (CT) ordered to evaluate shortness of
breath. The patient was 45 years old at the time. B, CT imaging 4
years later shows no growth in size and development of calcifica-
tion around the sac.
Table I. Clinical and demographic data on patients with S
Variable
Total (n  128)
Patients (%)
Female 89 (69.5)
Hypertension 66 (52)
Diabetes 11 (9)
Hyperlipidemia 56 (44)
Coronary artery disease 21 (16)
Any tobacco use 36 (28)
Current tobacco use 14 (11)
Abdominal symptoms 63 (49)
Mean age (years) 61  11
Initial SAA size (cm) 2.4  1.4 (n  124)
Follow-up (years) 4.9  3
SSA, Splenic artery aneurysm.
aComparison between observed and treated groups, P values are from Pearsderwent an emergency endovascular ablation. iPatients undergoing open surgery were treated via SAA
esection/splenectomy (7), ligation (4), or arterial recon-
truction (2) under general anesthesia. As stated above, six
atients underwent emergent laparotomy for rupture,
hereas the remaining seven underwent elective laparot-
my (4) or laparoscopic (3) aneurysm repair. There were
wo perioperative mortalities in this group. Both of these
eaths occurred in patients who presented with rupture,
epresenting a 29% mortality rate for ruptured SAA (2/7).
ther complications included postoperative hemorrhage
equiring a second laparotomy (n  2), a deep tissue
ound infection, and a pancreatic fistula that was treated
onservatively. Excluding the perioperative mortalities, the
edian length of stay was 9 days, significantly longer than
he length of stay for patients treated via an endovascular
ethod (1 day; P .001). Length of stay for patients with
uptured SAAs treated surgically was 27 days (n 4), while
t was 6 days for nonruptured SAAs treated surgically (n 
; P  .016)
Patients undergoing endovascular therapy were all
reated with endoluminal ablation under local anesthesia
ith sedation in 47 of 49 interventions. Percutaneous
nterventions were performed in dedicated endovascular
uites with fixed imaging. Femoral artery access was the
referred access site (69%), with brachial artery access used
n the remainder of instances. Splenic artery access was
aintained using a long 5F sheath (75.5%) in the vast
ajority of cases. Coil embolization was performed in 45 of
9 patients. N-butyl-2-cyanoacrylate (n-BCA, “glue”) was
sed adjunctively with coil embolization in 11 cases when
dequate exclusion of the aneurysm was not achieved with
oils only. Glue embolization was used solely in four cases.
echnical success was 96% (47 out of 49). One patient’s
rocedure was aborted secondary to intraoperative hypoten-
ion. The other failure was secondary to difficulty accessing
tortuous celiac axis. These two patients both had second
ttempts at a later date that were successful. There were no
onversions to open repair, nor was there any periproce-
ural mortality. Brachial artery access-site complications
rved (n  66)
atients (%)
Treated (n  62)
Patients (%) P valuea
52 (79) 37 (60) .03
36 (55) 30 (48) .6
5 (8) 6 (10) .9
32 (48) 24 (39) .4
10 (15) 11 (18) .9
17 (26) 19 (31) .7
3 (5) 11 (18) .035
32 (48) 31 (50) .99
64  12 58  10 .004
1.7  0.6 3.1  1.6 (n  58) .001
4.6  2.5 5.2  3 .24
tests for nominal variables and two sample t-tests for continuous variables.AAs
Obse
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access site hematoma required operative drainage.
With endovascular ablation of the splenic artery, the
fate of the patients’ spleen was carefully reviewed. Open
splenectomy for splenic abscess was required in two pa-
tients, 1 and 8 months after endovascular ablation. A third
splenic abscess required percutaneous drainage. Thus,
three out of 49 patients (6%) had clinically significant
splenic issues requiring reintervention. Postembolization
syndrome (PES) was considered in an additional five pa-
tients because of postoperative left upper quadrant pain
with or without a documented splenic infarct. In addition,
a review of images and radiology reports revealed some
evidence of postembolization splenic infarction in nine
other patients who did not have any symptoms or sequelae.
The location of treated SAA and symptomatic or asymp-
tomatic splenic abnormalities are displayed in Table III. A
majority of spleen-related adverse outcomes occurred after
distal SAA treatment.
Follow-up of patients with SAA included clinical eval-
uation (mean, 4.9  3 years; range, 7.6 months to 13.5
years) and serial axial imaging (mean, 2.7  2 years).
Observational criteria and timing of any follow-up was at
the discretion of the attending physician. Treated patients
received an average of 2.7 CT scans over 5.2 follow-up
years in the postoperative period (0.52/y). Observed pa-
tients received an average of 2.5 CT scans over 4.6
follow-up years (0.55/y). This included CT scans ordered
both on an elective basis for SAA surveillance and CT scans
ordered for other reasons wherein the left upper quadrant
was visualized. Multiple CT scans ordered during a single
inpatient admission were counted only as one time point.
There were no ruptures, adverse events, or mortalities
related to SAAs in the observed group. Serial imaging was
available for 62 (94%) of 66 patients, demonstrating a mean
aneurysm growth of 0.2 mm/y over 3.1 follow-up years
Table II. Comparisons of initial SAA size and calcification
Calcification Total
0
n Median (25th, 75th)
Initial size (cm) 110 18 2.7 (1.6, 3.7) 3
SSA, Splenic artery aneurysm.
0  no calcification, 1  40% circumferential calcification, 2  40% circ
Table III. The location of all treated SAA and spleen-rela
Location
All patients
(n  62)
Surgical treatment
(n  13)
Proximal 4 1
Mid 22 7
Distal 25 3
Hilum 11 2
SSA, Splenic artery aneurysm.
aIncludes splenic abscess (n  3), postembolization syndrome (n  5), and(Table IV). Postprocedure imaging of the SAA was avail- cble for 55 (89%) of the 62 treated patients. These patients
eceived serial CT scans (n  52), but a postoperative
ngiogram was used for imaging in a few patients (n  3).
reoperative and postoperative aneurysm size comparisons
ere available for 43 (88%) of the 49 patients in the
ndovascular group. Endovascular repair was associated
ith an average regression in aneurysm size of 1.5 mm/yr.
ne patient required an additional endoluminal procedure
or postprocedure aneurysm growth at 6 weeks for 4 mm
xpansion. Despite an association between calcification and
nitial SAA size, calcification of the aneurysm was not
ssociated with change in SAA size for either observed (P
28) or treated patients (P  .74).
Long-term survival is displayed in Fig 4 for patients
ith SAAs. Ten-year survival was 89.4% (95% confidence
nterval [CI]: 82.0, 97.4) for all patients. Patients in the
bservation group had a 10-year survival rate of 94.9%
95% CI: 87.8, 100), and the survival rate in the treated
roup was 85.1% (95% CI, 74.0, 97.9; P  .18). In this
ohort, there were eight deaths. The causes of death were
e
1 2
PMedian (25th, 75th) n Median (25th, 75th)
2.05 (1.6, 2.5) 54 1.75 (1.4, 2.5) .013
rential calcification.
utcomes after endovascular therapy
Endovascular treatment
(n  49)
Postembolization spleen
abnormalities (n  17)a
3 1
15 5
22 10
9 1
tomatic splenic infarction detected by CT review (n  9).
able IV. Summary of initial SAA size and change in
ize by group (note sizes are in mm)
ariable n Mean SD Range
nitial size (mm) – all patients 124 24 14 (8, 100)
nitial size (mm) – observed
patients 66 17 6 (8, 42)
hange in size (mm/y) –
observed patients 62 0.2 0.8 (2.2, 3.2)
nitial size (mm) – treated
patients 58 31 16 (15, 100)
hange in size (mm/y) –
treated patientsa 43 1.5 3.7 (20, 2.9)
D, Standard deviation; SSA, splenic artery aneurysm.
Endovascular only.scor
n
8ted oonfirmed through records review, and no additional SAA-
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who presented with rupture.
DISCUSSION
The pathogenesis of SAA has only been partially eluci-
dated. Histologic examinations have variously demonstrated
internal and external laminae disruption, fibrodysplasia of the
media, subendothelial thickening, and accretion of glycosami-
noglycans in the subintimal layer and media.3,10 Commonly
listed risk factors and associated diseases include atherosclero-
sis, autoimmune conditions (eg, lupus, vasculitides), collagen
vascular diseases, pancreatitis, and portal hypertension.11
There is a higher prevalence of SAA among women as seen in
our study. The influence of hormonal factors on arterial struc-
ture has been speculated but not confirmed.10 Splenic artery
pseudoaneurysm formation, although rare, has been associ-
ated with a history of pancreatitis, trauma, or surgical instru-
mentation.12
Irrespective of the mechanism of formation, the essen-
tial issue for physicians remains the clinical management of
patients and specifically the timing of any intervention.
Rapidly enlarging, symptomatic or ruptured SAAs require
treatment. Albeit a small group, ruptured SAAs carried an
extraordinary high mortality rate in our series. However,
controversy surrounds the treatment of silent, asymptom-
atic aneurysms. There is no single size criterion clearly
supported by the literature, although 2 cm is a commonly
cited cutoff.4,11,13 Based on our experience, we concur that
SAAs in the 2.0 to 2.5 cm range should be considered for
repair. Clearly, this decision making is in the context of
other clinical variables for an individual patient. There is
some evidence to suggest repair of SAAs regardless of size at
the time of liver transplantation and in women of childbear-
ing age given the propensity of these to rupture.10,14,15
Two of the seven ruptured SAAs in our series were patients
status-post liver transplant. The pregnant and/or multipa-
Fig 4. Kaplan-Meier estimates of overall survival are shown by
group. P .18, log-rank test, standard error (SE) 10% for both
curves throughout time interval.rous patient is also thought to be of higher risk, with taternal-fetal mortality increasing to over 75% in the set-
ing of rupture. Our cohort had five women of child-
earing age, all of whom were bioassay negative for preg-
ancy at the time of diagnosis and/or treatment.
Nearly half of all the patients in this series had abdominal
ain that prompted axial imaging and the finding of the SAA.
owever, only a small fraction of patients were thought to be
symptomatic” from the SAA. Patients considered for obser-
ation must have any episodes of abdominal pain definitively
ttributed to a pathology or process other than their SAA. In
ost cases, we performed serial imaging at an interval of 6
onths initially. Once absence or slow growth was confirmed,
erial imaging was performed every 1 to 2 years. The greatest
mount of growth for a patient under serial observation was
een in an 80-year-old female, whose aneurysm grew from 2.4
o 3.0 cm over 3 and 1/2 years. Most of the other patients’
neurysms had little to no growth over serial observation.
imilar to other aneurysms, clinicians should inform patients
f the signs and symptoms of ruptured SAA, and the impor-
ance of seeking immediate medical care in the face of sus-
ected rupture.
In our series, patients undergoing SAA treatment pre-
ented with larger aneurysms at a younger age. Five of the
even patients presenting with rupture were less than age
0. This suggests a divergence in the natural history from
hose aneurysms that will appear at a later point in life, and
row to a nominal size. Also, a younger patient will pre-
umptively be subjected to a longer period of serial imag-
ng, increasing the risks inherent to repeated radiation and
ntravenous contrast exposure.
An interesting finding in our study was the inverse
orrelation of SAA calcification and initial aneurysm size.
he more calcification present in the SAA, the smaller the
AA at presentation. However, we could not correlate
alcification with SAA rupture, a protective role against
neurysm growth nor as a factor in SAA contraction after
ndovascular therapy. A speculative conclusion may be that
gg-shell calcification early in aneurysm development will
revent expansion of the aneurysm.
SAAs may be treated via open or endovascular meth-
ds. We have adopted an endoluminal approach for the vast
ajority of SAAs using coil and/or glue embolization and
onsequent SAA ablation. The preference for endovascular
herapy is predicated on a low morbidity procedure per-
ormed under local anesthesia and allowing rapid recovery
fter a short hospital length of stay. Surgical therapy often
ccomplishes the same principle of SAA ablation with open
plenic artery ligation. In contradistinction, surgery for
AA can carry a 1% to 3% mortality rate, together with a 9%
o 25% perioperative complication rate from splenic or
ancreatic injury.1,3,11 A minority of our patients under-
ent surgical treatment for SAAs. Of these, nearly half were
or free rupture. Concomitant splenectomy was performed
n ruptured SAAs to expedite exposure and alleviate the
ossibilities of splenic infarction and rebleeding in critically
ll patients. We did successfully treat one contained rup-
ured by endovascular means. The role of the endovascular
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ruptured aneurysms, however, remains unclear.
The fate of the end-organ after endovascular emboliza-
tion of SAAs has been studied.4,7,16 Some patients may
experience PES in the perioperative period. Parameters
remain ill-defined, but typically include fever, pain, ileus,
platelet dysfunction, elevated white blood cell count, and
serologic evidence of pancreatitis. There has been a failure
to correlate radiographic findings of end-organ infarction
with constitutional complaints, laboratory findings, or in-
fectious process.16 Our results mirrored these findings. PES
did not correlate with splenic infarction. Conversely, some
completely asymptomatic patients had evidence of splenic
infarction on routine postprocedure imaging. The use of
n-BCA, solely or with coils, did not correlate with the
presence of splenic infarction. Glue was used adjunctively in
most cases if multiple coils failed to fill and occlude the
SAA. In addition, glue was used to occlude technically
evasive outflow vessels. The technical performance of glue
embolization requires assessment of polymerization time,
which dictates the dilution (usually 1:1) and instillation via
a coaxial 3F microcatheter. Polymerization within the SAAs
is critical to avoiding end-organ embolization and splenic
infarction. Despite our care in coil and glue embolization,
three patients treated via endovascular means (6%) required
secondary splenic procedures. Patients with distal SAAs
appeared to be at a higher risk for PES and/or asymptom-
atic splenic infarction. Postprocedure vigilance for splenic
infarction and abscess formation is warranted. On the other-
hand, patients with PES had symptom abatement with time
and surgical intervention was not needed.
The limitations of this study include the data gathering
inherent to retrospective studies. There was no randomiza-
tion of patients between treatment and observation. The
threshold for intervention was at the discretion of the
attending surgeon, and all aneurysms that were ruptured or
presumed to be symptomatic were treated. Any medical
treatment and follow-up regimen were not standardized.
Despite these limitations, this study does represent a large
review of patients with SAAs that were observed with modern
serial imaging allowing a glimpse at the natural history of SAAs.
We conclude that most asymptomatic, small (2.0 cm), heavily
calcified SAAs will not grow significantly over time, can be mon-
itored effectively with serial imaging, and carry a negligible rup-
ture risk. The number of incidentally detected SAAs will inevita-
bly rise, as high-resolution axial abdominal imaging continues to
be integrated into the standard of care for patients with a wide
variety of clinical issues.17 Based on our low morbidity rates and
absence of periprocedure mortality, endovascular ablation re-
mains a durable, effective treatment for SAAs that present with
larger size or grow over interval periods. Treatment of ruptured
SAAs is daunting and this remains a lethal entity. The time to
complete endovascular ablation may preclude use of this modal-
ity in patients with hemodynamic collapse. Future directions
must continue to focus on risk factors for rapid growth and Surther delineation of SAA natural history, which could ulti-
ately identify patients who benefit most from early prophylactic
ntervention.
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Dr Thomas Forbes (London, Ontario, Canada). Do your
recommendations change based on the age and the gender of the
patient, specifically a younger female of childbearing age?
Dr Lakin. Up to this point, I think our treatment recommen-
dations are based on size at presentation. Dr. Kashyap, did you
want to add anything to that?
Dr Kashyap. We do not have enough data on that particular
topic to answer that question. We only had five women in their
childbearing years in this series.
Dr Ronald Fairman (Philadelphia, Pa). Can you give us
some guidelines in terms of postoperative imaging requirements
after endovascular repair? How often do you need to reimage
them? Can you ever give up reimaging them?
Dr Lakin. From what we saw from our chart review, most of
the attendings would order a 3- to 6-month postablation image to
look for any size change and make sure there was an absence of
flow. And after that, there was serial imaging from about every 1 to
2 years. I think after you could document no growth after 2 years;
you can go 2 to 3 years.
Dr Amy Reed (Hershey, Pa). I have tended to just coil these
and have not done a lot with the glue. Can you give us some
guidelines, just technically, perhaps, on when you are putting
the glue in? Is it just when you see a blush after you coil, or when
is the time that you actually really need the glue?
Dr Kashyap. The glue is n-butyl cyanoacrylate. Ablation of
splenic artery or visceral aneurysms is an off-label use of a product
that is used commonly for cerebral AVMs. We usually dilute this
1-to-1 in terms of the injection. You have to dilute it with D5
rather than saline because of the polymerization that can occur. We
use it in large aneurysms in which after putting 5 or 8 or 10 coils,
one still has a large volume of the aneurysm sac that needs to be
filled. Also, if after coiling there is still flow, that is when the glue is
preferentially used.
Dr Ahmed Taha (El-Sheikh Zayed City, Egypt). It is amazing
to have this big series of splenic artery aneurysms. Were these all
atherosclerotic in nature? Did you perform any investigation to
settle the etiology of these aneurysms? Second, did the etiology
have an influence on your way of management? For example: Is it
justifiable to coil an inflammatory or mycotic aneurysm?
Dr Lakin. I cannot think of any diagnostic modality that
could help us out with the natural progression. I do not know. Dr
Kashyap, do you have an opinion on that?
Dr Kashyap. I am sorry. I did not understand that question.
Can you repeat it?
Dr Taha. Were these all splenic aneurysms atherosclerotic? Or
there was some sort of inflammatory or mycotic etiology? And if
there was more than one etiology, can the treatment be the same?
Dr Kashyap. That is a good question. And one of the things
that is very hard to discern is whether a patient has a true aneurysm
or a pseudoaneurysm, despite thin-cut CTs and other modalities. I
think in the clinical context of somebody that has a pancreatic tssue, it is usually a pseudoaneurysm. And there was a small
roportion of those patients in this series. Perhaps the most inter-
sting finding in our series is that the calcification may actually be
rotective. We assumed the calcification occurs over time. But, at
resentation, the more calcified splenic artery aneurysms were
uch smaller.
Dr Andres Katz (Dallas, Tex). I just have a couple of ques-
ions. One is, what was the incidence of splenic infarction after
mbolization? And second, have you considered laparoscopic re-
air? In my practice, I have been using robotic-assisted repair of
his lesion, which is relatively simple; it takes about an hour and a
alf, and you can either reconstruct the vessel after you excise the
neurysm or simply you can ligate the splenic artery aneurysm.
Dr Lakin. We had a 40% rate of radiographic evidence of
plenic infarction. That did not correlate with any follow-up symp-
oms or duration of pain. We did have the three splenic abscesses,
nd we had an additional five patients that required rehospitaliza-
ion or prolonged hospitalization for pain control. But in general,
nd this is supported by other literature, radiographic findings did
ot correlate with a clinical scenario.
Dr Walter Dorigo (Firenze, Italy). I have two short ques-
ions. The first, how many of your observed females were preg-
ant? And the other one, how did you observe during follow-up
our patient, with which diagnostic modality? And can you find
ome predictor of aneurysmal increase during follow-up?
Dr Lakin. We had five females of childbearing age. All had
ocumented negative pregnancy tests to get their imaging, so we
ad zero pregnancies in our cohort.
As far as follow-up, all but one or two had serial CAT scans. I
hink two had serial angiography.
Dr Ramesh Tripathi (New Delhi, India). From what I un-
erstand is that all your endovascular procedures involved occlu-
ion of the splenic artery. Do you always practice that, or do you
lso advocate preservation of the splenic artery by, say, stent-
ssisted coiling?
Dr Kashyap. The question is, should we be doing stent
rafting? And I think based on our results where we had very
inimal splenic loss or clinically significant splenic infarction, the
hort gastrics invariably feed the spleen and keep it alive. We did
ot see any issues with platelet function or number. I think coiling
nd ablating that artery is sufficient.
Dr Tripathi. I meant bare-stent assisted coiling.
Dr Kashyap. We do not have any experience with that tech-
ique.
Dr J. Gregory Modrall (Dallas, Tex). Did any patterns
merge with regard to those patients who had splenic infarcts? For
nstance, was the use of glue associated with a propensity for splenic
nfarction?Dr Lakin. No, we did not see any statistical correlation with
hose. We looked for those specifically. It was pretty random.
